Heart volume reduction implant

Abstract

The invention discloses a heart volume reduction implant, which comprises a contractile mesh plate, a choked flow membrane on the mesh plate, and a fixed plate connected with the mesh plate and located on one end of the mesh plate. The mesh plate is in a bowl shape. According to the heart volume reduction implant, aiming at the characteristics and the needs of minimally invasive treatment, particularly through the structure optimization of the mesh plate and the fixed plate, the contractility of the mesh plate is improved, and the heart volume reduction implant can be favorably loaded in a conveying system, so that the diameter of a conveying conduit can be reduced, and the damage of the implantation process to blood vessel wall tissues is reduced. The superelasticity of the implant is utilized, so that a balloon dilatation manner has no need to be adopted during the implantation process; in addition, the implant has a repeat positioning operation function, so that the surgical operation is convenient and simple. The implant is suspended and fixed on a heart ventricle wall by utilizing the fixed plate so as not to contact with a cardiac apex, so that the damage of the heart volume reductionimplant to the cardiac apex of a patient is avoided.

Description

technical field [0001] The invention relates to the technical field of heart surgery instruments, in particular to a heart volume reduction implant. Background technique [0002] In today's clinical treatment, the heart (such as figure 1 ), especially congestive heart failure (CHF) characterized by hypertrophy or dilation of the left ventricle is a major cause of death and disability. As the patient's ventricles enlarge, the heart becomes less and less efficient at pumping blood. Gradually, the heart becomes more enlarged so that it cannot supply enough blood to the body. Medicine uses ejection fraction to judge whether a patient's heart is healthy. Ejection fraction refers to the ability of the blood in the ventricle to pump outward every second. The snake blood fraction of a normal healthy heart is about 60%, while the ejection fraction of CHF patients is usually only 40% or even less. CHF patients experience constant fatigue, physical disability, and pain and discomfor...

AI Technical Summary

Problems solved by technology

[0005] However, the above-mentioned "parachute" and its implantation method have the following defects: 1. The supporting base of the existing "parachute" product is made of polymer materials, and the diameter of the base is still large after being compressed, resulting in the required transportation. The outer diameter of the catheter should exceed 14Fr. Therefore, the operation of implanting the "parachute" through the delivery catheter will seriously damage the inner wall tissue of the blood vessel; 2. The base of the existing "parachute" is not flexible enough to adjust the height of the parachute product , so during the release operation, it is necessary to ensure that the base is completely attached to the apex of the ventricle, which requires extremely high technical requirements for the operator and directly affects the promotion of technology; 3. The existing "parachute" products cannot be repeatedly positioned. The release position is improper, and the parachute cannot be retracted, that is, the repeated positioning of the product cannot be realized; 4. The existing surgical method of implanting a "parachute" needs to use a balloon to expand the insulating layer after the insulating layer is released, which will inevitably increase the cost of the operation. Operating time; 5. After the existing "parachute" product is released, the support base needs to be in constant contact with the inner wall of the apex of the heart. During the continuous beating of the heart, the inner wall of the apex of the heart will inevitably be rubbed by the support base, resulting in damage to the patient's apex. damage

Images